NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Fortress Biotech, Inc. FBIO
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$61.2M
▲ 11.1% vs FY2024
EPS · FY25
$-0.07
Dividend / sh · FY25
—
Payout · FY25
10%
ROE · FY25
18.8%
Net margin · FY25
11.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 61.2M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
11 cents of every revenue dollar became profit this year.
Per share
USD -0.07
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
18.8%
Return on equity, FY2025
ROE
Operating margin-114.7%
Net margin11.1%
Return on assets4.1%
Each USD of equity produced 19 cents of profit this year.
Returned to shareholders
USD 664,000.00
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 664,000.00
Net buybacks—
Share of profit9.7%
Consecutive raises—
USD 664,000.00 in dividends — 10% of the year's profit went back to shareholders.
Growth
+6.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−4.8%
+6.6%
+53.1%
Returned to shareholders
−3.9%
+22.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+107.3%
Change, 10 years—
The share count grew 107% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 185.5M
total assets, end of FY2025
Total assetsUSD 185.5M
EquityUSD 49.9M
CashUSD 79.4M
Gross debtUSD 52.4M
Net debtUSD -27.0M
Current ratio2.49×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.1
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
Net income $B
0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.07
−2.69
−8.47
−15.97
−0.79
−0.65
−0.73
−1.94
−1.61
−1.38
−1.24
−0.56
−1.22
−1.27
−5.51
−2.24
−1.01
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
10
−2
−1
−1
−1
−1
−0
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
18.8
−203.2
−188.7
−115.1
−61.9
−73.5
−284.7
−309.2
−146.9
−115.6
−76.0
−26.9
−71.9
−134.1
−2247.9
·
·
·
·
Shares out B
0.03
0.03
0.02
0.01
0.10
0.09
0.07
0.06
0.05
0.05
0.05
0.05
0.04
0.02
0.02
0.00
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed